Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: psilocybin Clear all
Completed Phase 1 Interventional

PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643
View directory record Official record
Conditions
Depression, Burnout, Professional
Interventions
Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin (0.25mg/kg), Niacin (250mg)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT01988311
View directory record Official record
Conditions
Psilocybin, Hallucinogens, Pharmacologic Actions, Central Nervous System Agents, Therapeutic Uses, Psychotropic Drugs
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06067737
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

NCT06626139
View directory record Official record
Conditions
Healthy Participants With Lower-than-average Mental Well-being
Interventions
Psilocybin, Context 1, Context 2, Placebo
Drug · Behavioral
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Active, not recruiting Phase 2 Interventional

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

NCT07336238
View directory record Official record
Conditions
Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Psychotherapy, Psilocybin, Survey Administration
Behavioral · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

NCT06592833
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin, Pimavanserin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Early Phase 1 Interventional

Psilocybin-facilitated Treatment for Chronic Pain

NCT05068791
View directory record Official record
Conditions
Fibromyalgia, Primary
Interventions
Psilocybin, Dextromethorphan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

NCT06902974
View directory record Official record
Conditions
Post Traumatic Stress Disorder, PTSD
Interventions
Psilocybin 25 mg
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Psychedelics in Healthy Older Adults With Low Well-being

NCT07386730
View directory record Official record
Conditions
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions
Psilocybin (drug), Dextromethorphan (DXM)
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Albuquerque, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

NCT06814522
View directory record Official record
Conditions
Burnout, Burnout, Healthcare Workers
Interventions
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Real-time Biofeedback
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

NCT06989957
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Psilocybin, MDMA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

NCT05847686
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Counseling, Psilocybin, Questionnaire Administration
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety for Home Administration of Microdose Psilocybin Use

NCT06450210
View directory record Official record
Conditions
Psychedelic Experiences
Interventions
psilocybin trihydrate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Active, not recruiting Phase 1 Interventional

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Psilocybin, Placebo, Medium Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for Intergenerational Trauma

NCT06899165
View directory record Official record
Conditions
Psychological Stress, Depression, Anxiety
Interventions
Psilocybin, Integration sessions
Drug · Behavioral
Lead sponsor
Rachel Yehuda
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Maryland Oncology Hematology, PA
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 18, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Effects of Psilocybin in Major Depressive Disorder

NCT03181529
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 18, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

NCT07347405
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 18, 2026, 2:26 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

NCT05317689
View directory record Official record
Conditions
Healthy
Interventions
Psilocin, Psilocybin, Sublingual Psilocin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 18, 2026, 2:26 PM EDT